Ongoing Clinical Trials for Contusion
This article provides information about ongoing clinical trials investigating new treatments for contusion. Currently, there is 1 active trial examining a topical pain relief system for bruises of the arms and legs. The trial is being conducted in Germany and compares a skin patch containing esflurbiprofen with oral paracetamol for managing pain from recent contusions.
Clinical trial locations
Study on Esflurbiprofen and Paracetamol for Pain Relief in Patients with Limb Bruises
This clinical trial is investigating a new approach to treating pain from acute bruises on the arms or legs. The treatment being tested is called the Esflurbiprofen Topical System (EFTS), which is a medicated patch that you apply directly to the skin over the bruised area. The patch contains esflurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID) designed to reduce pain and inflammation locally where the injury occurred.
Main inclusion criteria:
- You must have a recent bruise on your arm or leg that occurred within the past 6 hours
- The bruise should cause pain when you move the affected area, with a pain score greater than 50 mm on a 100 mm scale
- The size of the bruised area should be between 25 cm² and 120 cm²
- You must be between 18 and 64 years old
- Your overall health should be satisfactory according to the study doctor
- You need to provide written informed consent to participate
Main exclusion criteria:
- The trial excludes vulnerable populations who may be unable to provide proper consent
- Specific age restrictions apply, limiting participation to adults within a defined age range
Trial focus and goals:
The main purpose of this study is to assess how safe and effective the Esflurbiprofen Topical System is in providing short-term pain relief for bruises. Participants will use the patch for up to seven days, during which researchers will monitor how well it works and whether any side effects occur. The study will also compare the patch’s effectiveness to oral paracetamol, a commonly used pain reliever taken as tablets.
Throughout the trial, you will be asked to report your pain levels at regular intervals, including before bedtime on specific days. The researchers are particularly interested in measuring how long it takes for pain to decrease by meaningful amounts—specifically by 30% and 50%—and how long it takes for pain to resolve completely. The study will track pain both when you are moving and when you are at rest.
Regular check-ins will ensure the treatment is working as intended and monitor for any skin reactions to the patch. At the end of the trial, both you and your doctor will provide an overall assessment of how effective the treatment was using a standardized rating scale.
Investigational drug:
The Esflurbiprofen Topical System (EFTS) is the main treatment being tested. This is a transdermal patch that delivers the medication esflurbiprofen through the skin directly to the injured area. Esflurbiprofen belongs to a class of medications called NSAIDs, which work by blocking the production of certain chemicals in the body that cause inflammation and pain. By applying the medication directly to the skin over the bruise, the goal is to provide targeted pain relief while potentially minimizing side effects that can occur with oral pain medications.
Summary
Currently, there is one ongoing clinical trial for contusion treatment, focusing specifically on acute bruises of the arms and legs. This trial is taking place in Germany and represents a targeted approach to pain management through topical treatment rather than oral medications.
The study is notable for its comparison between a localized treatment approach—the Esflurbiprofen Topical System patch—and the widely used oral pain reliever paracetamol. This comparison may help determine whether applying medication directly to the injured area offers advantages over traditional oral pain medications.
The trial has specific requirements regarding the timing of treatment, requiring participants to enroll within 6 hours of injury, which emphasizes the importance of early intervention in managing bruise-related pain. The study’s focus on measuring both meaningful and complete pain reduction provides detailed information about how quickly and effectively the treatment works.
For patients with recent bruises who meet the eligibility criteria, this trial offers an opportunity to access a potentially innovative pain management approach while contributing to research that may benefit others with similar injuries in the future.